Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 8/20 | 0.37 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | EIF4E | P06730 | 1/20 | 0.34 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25552092 | 0.82 | KMO (0.40) | KMOMEN1KMT2ABTKALDH1A1 | |
| SCHEMBL30156974 | 0.81 | KMO (0.44) | KMOMEN1KMT2ABTKALDH1A1 | |
| SCHEMBL25551849 | 0.81 | KMO (0.44) | KMOMEN1KMT2ABTKALDH1A1 | |
| SCHEMBL25210572 | 0.80 | HCAR2 (0.42) | HCAR2KMO | |
| SCHEMBL25551989 | 0.80 | HCAR2 (0.38) | HCAR2KMOPLAUEGLN1ALDH1A1 | |
| SCHEMBL25210699 | 0.80 | KMO (0.55) | KMOCSNK2A2CSNK2B | |
| SCHEMBL25211840 | 0.78 | KMO (0.43) | KMOBTK | |
| SCHEMBL25234137 | 0.78 | KMO (0.46) | KMOCSNK2A2CSNK2B | |
| SCHEMBL25257521 | 0.75 | KMO (0.59) | KMOBTKCSNK2A2CSNK2BEGLN1 | |
| SCHEMBL30037621 | 0.74 | KDM4E (0.41) | HCAR2KMOMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565490-B2 | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-03 | — | — | US | disclosed |
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-25 | — | — | US | disclosed |
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-05-25 | — | — | US | disclosed |
| EP-4110765-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | Board of Regents, The University of Texas System (US) | 2023-01-04 | — | — | EP | disclosed |
| CN-115515940-A | Inhibitors of receptor interacting protein kinase I for the treatment of disease | 德州大学系统董事会 | 2022-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159508-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | HCAR2 979/4885KMO 3071/4885FTO 4698/4885 |
| US-12565490-B2 | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | RIPK1, RIPK4, RIPK2 | HCAR2 243/4885KMO 2319/4885FTO 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.